The management of saleable returns in the U.S. pharma industry has traditionally fallen under the remit of wholesalers. Track-and-trace regulations in the form of the Drug Supply Chain Security Act (DSCSA) are forcing the industry to revisit that model. The key DSCSA milestone is November 2019, at which point wholesalers will be required to verify…